This study outlines a roadmap significantly expediting the approval process for gene therapies used in rare pediatric diseases. Key strategies include pre-aligned regulatory documentation, collaborative patient recruitment management, and the establishment of a data sharing platform for expedited clinical outcome validation. Implementation of these measures could potentially reduce approval timelines from several years to approximately 1-2 years.